ClinicalTrials.gg
CompletedNCT06550830Updated Jan 28, 2026

Clinical Trial of PCV24 in Children Aged 2-17 Years

A Phase 1 interventional study of Sinovac PCV24 formulation 1 and Sinovac PCV24 formulation 2 in Pneumococcal Infectious Disease, sponsored by Sinovac Life Sciences Co., Ltd.. Completed at 1 site in China. Open to participants aged 2 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Sinovac Life Sciences Co., Ltd. (part of Sinovac Biotech Co., Ltd) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Pneumococcal Infections by Sinovac Biotech Co., Ltd — 3 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal Infections · Sinovac Biotech Co., Ltd.

Enrollment
12th of 12
119 · median 403
Started
2024
with 3 others
Phase 1
5 of 13
1 open now
Registered
8th of 13
by date

Among the 13 studies in Pneumococcal Infections by Sinovac Biotech Co., Ltd, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2024, is one of 5 in phase 1, and was the 8th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

3 of the 13 studies in Pneumococcal Infections by Sinovac Biotech Co., Ltd are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Pneumococcal Infections by Sinovac Biotech Co., Ltd, or all of them as a file.
02

Study summary

A Phase Ia clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2-17 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, controlled combined with open-label phase Ia clinical trial.

Read the detailed description

A phase Ia clinical trial of the study of 24-valent Pneumococcal Conjugate Vaccine (PCV24) developed by Sinovac Life Science Co., Ltd (Sinovac) will be conducted in Chinese children aged 2-17 years. The trial is a randomized, double-blind, controlled combined with open-label study. The objective of this study is to evaluate the safety and immunogenicity of PCV24 manufactured by Sinovac Life Science Co., Ltd. The active control vaccine for participants aged 2-5 years is the Prevenar13® manufactured by Pfizer.

A total of at least 114 participants will be enrolled, including 24 children aged 6-17 years and 90 children aged 2-5 years. Children aged 6-17 years will receive PCV24 formulation 1 and PCV24 formulation 2 in a 1:1 ratio. Children aged 2-5 years will receive PCV24 formulation 1, PCV24 formulation 2 and Prevenar13® in a 1:1:1 ratio.

03

Conditions studied

  • Pneumococcal Infectious Disease
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy volunteers who are aged 2-17 years;
  2. Participants and their guardians provide legal proof of identity, as well as vaccination record (for children aged 2-5 years);
  3. Participants' guardians understand and voluntarily sign the form; participants aged 8-17 years sign the written assent;
  4. Participants can follow all study procedures and stay in contact during the study.

Exclusion criteria

Exclusion Criteria:

  1. Received any pneumococcal vaccine prior to enrollment;
  2. History of invasive pneumococcal diseases (IPDs) or other pneumococcal diseases caused by Streptococcus pneumoniae, as confirmed by laboratory tests;
  3. History of allergy or adverse reactions to the vaccine or vaccine components, or history of allergy, such as urticaria, dyspnea, angioedema and anaphylactic shock;
  4. Congenital malformations or developmental disorders, genetic defects (such as Down syndrome, thalassemia, or G6PD deficiency), severe malnutrition;
  5. Have uncontrolled chronic diseases or history of severe diseases, including but not limited to cardiovascular diseases, such as cardiovascular diseases (e.g. congenital heart disease), metabolic diseases (such as diabetes), hematological diseases (e.g. severe anemia),liver and kidney diseases, digestive diseases, respiratory diseases (such as active tuberculosis), malignant tumors and major functional organ transplantation history;
  6. diseases or immunodeficiency diseases (including but not limited to systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroid disease, asplenia, functional asplenia, infection)
  7. Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal level), history of obvious bleeding, hematoma or bruising after intramuscular injection or venipuncture.
  8. Have/have suffered from a serious neurological disorder (epilepsy or convulsions) or mental illness or have a family history of such diseases.
  9. Long-term alcohol or drug abuse.
  10. Have received > 14 days of or other immunomodulatory therapy in the past 6 months, or cytotoxic therapy, or plan to receive such therapy during the study period.
  11. Received immunoglobulin or other blood products within 3 months prior to enrollment, or plan to receive such treatment during the study period;
  12. Received other drugs or vaccines within 30 days prior to enrollment, or plan to receive such drugs or vaccines during the study;
  13. Received within 14 days prior to enrollment;
  14. Received subunit or inactivated or other vaccine within 7 days prior to enrollment;
  15. Acute diseases or acute onset of chronic diseases within 7 days prior to enrollment, or known or suspected active infection;
  16. Women who are pregnant or breastfeeding (if applicable);
  17. Abnormalities in clinical laboratory indicators that exceed reference range and are .
  18. Had fever (axillary temperature> 37.0℃) before vaccination;
  19. In the investigator's judgment, the participant has any other factors that make him or her unfit to participate in the clinical trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Experimental group 1

    12 participants aged 6-17 years and 30 participants aged 2-5 years will be randomized to receive Sinovac PCV24 formulation 1. Route of administration is intramuscular injection at deltoid muscle of upper arm. Immunization schedule is 1 dose.

    Biological: Sinovac PCV24 formulation 1

  • Experimental
    Experimental group 2

    12 participants aged 6-17 years and 30 participants aged 2-5 years will be randomized to receive Sinovac PCV24 formulation 2. Route of administration is intramuscular injection at deltoid muscle of upper arm. Immunization schedule is 1 dose.

    Biological: Sinovac PCV24 formulation 2

  • Active comparator
    Active control group

    30 participants aged 2-5 years will be randomized to receive Prevenar13®. Route of administration is intramuscular injection at deltoid muscle of upper arm. Immunization schedule is 1 dose.

    Biological: Prevenar13®

Interventions

  • BiologicalSinovac PCV24 formulation 1

    One dose of Sinovac PCV24 formulation 1(0.5mL)

  • BiologicalSinovac PCV24 formulation 2

    One dose of Sinovac PCV24 formulation 2(0.5mL)

  • BiologicalPrevenar13®

    One dose of PCV13 manufactured by Pfizer

06

What researchers measure

Primary outcomes

  1. Incidence of adverse reactions

    Incidence of adverse reactions within 30 days after vaccination

    Time frame: 0-30 days after vaccination

Secondary outcomes

  1. Incidence of adverse reactions

    Incidence of adverse reactions within 7 days after vaccination

    Time frame: 0-7 days after vaccination

  2. Incidence of serious adverse events (SAE)

    Incidence of SAE during the period of safety monitoring

    Time frame: 0-6 months after vaccination

  3. Incidence of clinically significant abnormality in laboratory examination tests

    Incidence of clinically significant abnormality in blood routine, blood biochemistry and urine routine test results within 3 days after vaccination

    Time frame: 0-3 days after vaccination

  4. Pneumococcal serotype-specific IgG antibody geometric mean concentration (GMC)

    IgG GMC 30 days after vaccination

    Time frame: 30 days after vaccination

  5. Proportion of Pneumococcal serotype-specific IgG antibody concentration ≥0.35 μg/ml (seropositive rate)

    Proportion of IgG antibody concentration ≥0.35 μg/ml

    Time frame: 30 days after vaccination

  6. Proportion of Pneumococcal serotype-specific IgG antibody concentration ≥1.0 μg/ml

    Proportion of IgG antibody concentration ≥1.0 μg/ml

    Time frame: 30 days after vaccination

  7. Pneumococcal serotype-specific IgG antibody geometric mean increase (GMI)

    IgG GMI 30 days after vaccination

    Time frame: 30 days after vaccination

  8. Proportion of pneumococcal serotype-specific IgG antibody concentration increase≥4

    Proportion of IgG antibody concentration increase≥four folds 30 days after vaccination

    Time frame: 30 days after vaccination

  9. Pneumococcal serotype-specific opsonophagocytic assay (OPA) geometric mean titer (GMTs)

    OPA GMT 30 days after vaccination

    Time frame: 30 days after vaccination

  10. Pneumococcal serotype-specific OPA GMI

    OPA GMI 30 days after vaccination

    Time frame: 30 days after vaccination

  11. Proportion of Pneumococcal serotype-specific OPA GMT≥1:8

    Proportion of Pneumococcal serotype-specific OPA GMT≥1:8 30 days after vaccination

    Time frame: 30 days after vaccination

  12. Proportion of pneumococcal serotype-specific OPA antibody titer increase≥4

    Proportion of OPA antibody titer increase≥four folds 30 days after vaccination

    Time frame: 30 days after vaccination

07

Study locations

1 site
  • Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine)
    Nanjing, Jiangsu, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Jun 2025, 9 months.

Of 27 phase 1 interventional studies under Pneumococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Aug 13, 2024
StartActual
Sep 7, 2024
Primary completionActual
Jun 25, 2025
CompletionActual
Jun 25, 2025
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06550830
Responsible party
Sponsor
First posted
Aug 13, 2024
Start date
Sep 7, 2024
Primary completion
Jun 25, 2025
Completion
Jun 25, 2025
Last update
Jan 28, 2026

Study contacts

Kai Chu
principal investigator · Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion